Journal article Open Access

EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS.

Lenka D.N.; Routray S.N.


DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:cnt="http://www.w3.org/2011/content#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://doi.org/10.5281/zenodo.3365128">
    <rdf:type rdf:resource="http://www.w3.org/ns/dcat#Dataset"/>
    <dct:type rdf:resource="http://purl.org/dc/dcmitype/Text"/>
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.5281/zenodo.3365128</dct:identifier>
    <foaf:page rdf:resource="https://doi.org/10.5281/zenodo.3365128"/>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Lenka D.N.</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Senior Resident, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Routray S.N.</foaf:name>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>Professor, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS.</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2019</dct:issued>
    <dcat:keyword>Blood Pressure Azilsartan Telmisartan.</dcat:keyword>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2019-07-01</dct:issued>
    <owl:sameAs rdf:resource="https://zenodo.org/record/3365128"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/3365128</skos:notation>
      </adms:Identifier>
    </adms:identifier>
    <dct:isVersionOf rdf:resource="https://doi.org/10.5281/zenodo.3365127"/>
    <dct:description>&lt;p&gt;Objective: Angiotensive receptor blockers (ARBs) are very potent antihypertensive agents , Telmisartan being the prototype and most widely used.This study was undertaken to compare the efficacy and safety of Azilsartan a new ARB with Telmisartan. Material and methods : This prospective study was carried out in patients attending the Department of Medicine, SCB Medical college, Cuttack. Patients with newly diagnosed with stage I-II essential hypertension of either sex within the age group of 18?65 years with blood pressure of &amp;ge;140/90 mmHg were included in the study. Severe hypertension &amp;gt;180/110 mm of Hg, hypersensitivity to ARBs, secondary hypertension with any other etiology, pregnant women, history of Drug/ Alcohol abuse, cardiac arrhythmias were excluded. Patients who gave consent for the study were divided into 2 random groups 1 and 2 ? the first received azilsartan and the second received telmisartan. Point of control was defined as blood pressure&amp;lt;140/90 mm of Hg after initiation of therapy. Results : 180 patients were randomized into two groups. Out of 90 patients included in group 1 who received azilsartan, 4 lost for follow up. Out of 90 patients included in group 2 who received telmisartan, 5 lost for follow up. There was no significant difference between the two drugs in both mean systolic and diastolic blood pressure at 24hrs, 1 month and 3 months and 6 months. Mean diastolic blood pressure at 24 hrs was reduced more with telmisartan compared to azilsartan which is significant. Hypotension related adverse effects occurred in 3% of the patients in azilsartan group while it occurred in 8% of them in telmisartan group. Conclusion: Azilsartan is an effective blood pressure lowering drug with its safety and efficacy comparable to that of telmisartan.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dcat:distribution>
      <dcat:Distribution>
        <dct:license rdf:resource="http://creativecommons.org/licenses/by/4.0/legalcode"/>
        <dcat:accessURL rdf:resource="https://doi.org/10.5281/zenodo.3365128"/>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
</rdf:RDF>
22
10
views
downloads
All versions This version
Views 2222
Downloads 1010
Data volume 3.5 MB3.5 MB
Unique views 2222
Unique downloads 99

Share

Cite as